: Rated as one of the most undervalued "Best Companies to Own" by Morningstar, with a price-to-fair value ratio of approximately 0.59.

: Noted for accelerating growth in its commercial segment, with a CFRA price target of $203.

The best-performing stocks so far this year are heavily concentrated in specialized semiconductors and biotech.